Applied Molecular Transport Inc. (AMTI) Bundle
A Brief History of Applied Molecular Transport Inc. (AMTI)
Foundation and Early Developments
Applied Molecular Transport Inc. (AMTI) was founded in 2016. The company was established to develop its novel technology platform aimed at transforming the delivery of therapeutics using its proprietary Transport Vehicle system.
Initial Funding Rounds
In its early years, AMTI secured funding through various rounds. The company raised $9 million in a Series A funding round in 2018. Later on, in 2020, AMTI completed a Series B funding round, raising approximately $35 million.
Public Offering
AMTI went public on the NASDAQ under the ticker symbol AMTI on August 6, 2020. The initial public offering (IPO) was priced at $18 per share, raising $105 million in total.
Research and Development Progress
AMTI has focused heavily on its research and development efforts. In 2021, the company reported a total research and development expense of $20 million as it advanced its therapeutic candidates.
Clinical Trials and Pipeline
As of 2023, AMTI has initiated multiple clinical trials. The lead candidate, AMT-101, is being assessed in Phase 2 studies for the treatment of ulcerative colitis. The company’s product pipeline also includes various other candidates targeting different disease areas.
Financial Performance
For the year ended December 31, 2022, AMTI reported total revenue of $5 million. The net loss for the same period was approximately $35 million. As of June 30, 2023, AMTI had cash and cash equivalents amounting to $50 million.
Partnerships and Collaborations
- In 2022, AMTI entered into a collaboration agreement with a major biopharmaceutical company to leverage its Transport Vehicle technology.
- The partnership is aimed at expanding the application of its delivery system in multiple therapeutic areas.
Recent Developments and Future Directions
AMTI continues to focus on expanding its clinical programs and strengthening its financial position. The company aims to initiate further clinical trials throughout 2023 and beyond.
| Year | Funding Rounds | Revenue | Net Loss | Cash and Cash Equivalents |
|---|---|---|---|---|
| 2018 | $9 million (Series A) | - | - | - |
| 2020 | $35 million (Series B) | $105 million (IPO) | - | - |
| 2021 | - | - | $20 million (R&D Expense) | - |
| 2022 | - | $5 million | $35 million | - |
| 2023 | - | - | - | $50 million |
Market Position and Competitors
AMTI operates in a competitive landscape with several notable companies in the biotech sector. The company distinguishes itself through its unique delivery system, which is designed to enhance the effectiveness of therapies.
A Who Owns Applied Molecular Transport Inc. (AMTI)
Shareholder Composition
As of the latest filing, the ownership structure of Applied Molecular Transport Inc. (AMTI) is comprised of institutional investors, retail investors, and company insiders.
| Owner Type | Percentage Owned | Owner Name | Shares Owned |
|---|---|---|---|
| Institutional Investors | 64.5% | BlackRock, Inc. | 1,000,000 |
| Institutional Investors | 9.8% | Vanguard Group | 500,000 |
| Insiders | 5.2% | CEO, Aidan M. O’Sullivan | 300,000 |
| Retail Investors | 20.5% | Various | 1,000,000 |
Current Market Valuation
The market capitalization of Applied Molecular Transport Inc. (AMTI) is approximately $213 million.
Stock Performance
The stock price of AMTI as of the last trading session was $4.50 per share, with a year-to-date performance of approximately -25%.
Recent Funding Rounds
Applied Molecular Transport Inc. recently completed a funding round that raised $50 million to advance its pipeline and operational capabilities.
Key Institutional Shareholders
| Institution | Shares Held | Percentage of Total Shares |
|---|---|---|
| BlackRock, Inc. | 1,000,000 | 15.2% |
| Vanguard Group | 500,000 | 9.5% |
| State Street Corporation | 400,000 | 7.0% |
Insider Summary
Insider ownership is a vital aspect of the company’s equity structure. The following table summarizes key insiders:
| Insider Name | Title | Shares Owned | Ownership % |
|---|---|---|---|
| Aidan M. O’Sullivan | CEO | 300,000 | 5.2% |
| John Doe | CFO | 150,000 | 2.6% |
| Mary Smith | Board Member | 50,000 | 0.5% |
Recent Changes in Ownership
In the past quarter, there was a reported 10% increase in institutional ownership, reflecting an increase in confidence among large investors.
Conclusion on Ownership Trends
The ownership trends of Applied Molecular Transport Inc. indicate a predominantly institutional investor base, with insiders maintaining a notable stake.
Applied Molecular Transport Inc. (AMTI) Mission Statement
Overview of AMTI
Applied Molecular Transport Inc. is focused on the development of a novel platform for the delivery of therapeutics. The company’s mission is to leverage its proprietary technology to improve patient outcomes by enhancing the delivery of medicines to the intended target tissues.
Core Mission Statement
The mission statement of AMTI emphasizes their commitment to transform the treatment landscape for patients through innovative delivery solutions. The core aspects include:
- Enhancing therapeutic outcomes.
- Reducing the side effects of therapies.
- Facilitating patient compliance and adherence.
Financial Performance
As per the latest financial filings for the fiscal year ending December 31, 2022, AMTI reported the following key figures:
| Metric | 2022 Amount | 2021 Amount |
|---|---|---|
| Total Revenue | $2.3 million | $1.1 million |
| Net Loss | $(28.4) million | $(25.6) million |
| Cash and Cash Equivalents | $50.1 million | $18.5 million |
| Research and Development Expenses | $18.5 million | $14.0 million |
Research and Development Focus
AMTI has dedicated a substantial portion of its resources to research and development, emphasizing the innovative approaches in drug delivery systems. The main areas of focus include:
- Nanoparticle-based delivery systems.
- Innovative oral delivery mechanisms.
- Collaboration with pharmaceutical companies for drug formulation.
Strategic Partnerships
AMTI's strategy includes establishing partnerships with key players in the pharmaceutical sector. As of 2023, the following partnerships are in place:
| Partner | Focus Area | Start Year |
|---|---|---|
| Company A | Oncology Therapies | 2021 |
| Company B | Autoimmune Diseases | 2022 |
Market Potential
The potential market for AMTI's therapeutic delivery systems is significant. According to reports from the global pharmaceutical market, the following figures illustrate the market opportunity:
| Market Segment | Estimated Value (2023) | Projected CAGR (2023-2030) |
|---|---|---|
| Targeted Drug Delivery | $24.6 billion | 12.8% |
| Nanomedicine | $179.6 billion | 10.5% |
Commitment to Sustainability
AMTI is also committed to sustainable practices in their operations. They have outlined key sustainability goals for 2023:
- Reduce carbon footprint by 20%.
- Achieve zero waste in manufacturing processes.
- Implement green chemistry principles in R&D.
How Applied Molecular Transport Inc. (AMTI) Works
Company Overview
Applied Molecular Transport Inc. (AMTI), based in South San Francisco, California, focuses on developing a novel platform for the delivery of biologic therapeutics using its proprietary technology. This technology is designed to enhance the efficacy of drugs by enabling oral delivery of biologics, which traditionally require injection.
Technology Platform
The company's core technology relies on its Transport Vehicle (TV) platform, which facilitates the oral delivery of large-molecule therapeutics. The key components include:
- Nanoparticle formulation
- Molecular targeting strategies
- Enhanced absorption capabilities
Pipeline Products
AMTI's product pipeline includes:
- AMT-101: A treatment for ulcerative colitis, currently in Phase 2 clinical trials.
- AMT-126: A potential therapy for immunological disorders, with ongoing preclinical studies.
- Strategic partnerships with pharmaceutical companies
- Focus on rare diseases and unmet medical needs
- Investment in clinical trials to validate technology
- Successful completion of Phase 1 clinical trials for AMT-101.
- Collaboration with a major pharmaceutical company to co-develop AMT-126.
- Presentation of data at industry conferences, enhancing visibility.
- Clinical trial failures
- Regulatory hurdles
- Competition from other biopharmaceutical companies
- Continued development of pipeline candidates
- Pursuit of strategic collaborations
- Focus on expanding intellectual property portfolio
- AMT-101: A treatment for ulcerative colitis.
- AMT-126: Targeting autoimmune diseases.
- AMT-201: Focused on immunotherapy.
- Strategic partnerships with major pharmaceutical companies.
- Increased investment in clinical trials for pipeline products.
- Exploration of international markets to enhance revenue streams.
- Regulatory hurdles associated with drug approval.
- Competition from established pharmaceutical companies.
- Dependence on continued funding and investment.
Financial Performance
As of the second quarter of 2023, AMTI reported the following financial figures:
| Financial Metric | Value (in millions) |
|---|---|
| Total Revenue | $0.5 |
| Net Loss | $(20.3) |
| Cash and Cash Equivalents | $39.4 |
| R&D Expenses | $9.2 |
| General and Administrative Expenses | $4.1 |
Market Strategy
AMTI's market strategy consists of:
Recent Developments
Recent milestones achieved by AMTI include:
Stock Performance
As of October 2023, AMTI is traded on the NASDAQ under the ticker symbol AMTI. The following data reflects its recent stock performance:
| Date | Stock Price (USD) | Market Capitalization (in billions) |
|---|---|---|
| October 1, 2023 | $2.15 | $0.1 |
| October 15, 2023 | $2.35 | $0.11 |
| October 30, 2023 | $2.50 | $0.12 |
Challenges and Risks
AMTI faces various challenges and risks, which include:
Future Outlook
The outlook for AMTI incorporates:
How Applied Molecular Transport Inc. (AMTI) Makes Money
Revenue Streams
Applied Molecular Transport Inc. primarily generates revenue through the development and commercialization of innovative drug delivery systems focused on oral treatments for various diseases.
Licensing and Collaboration Agreements
In 2022, AMTI entered several collaboration agreements, including a key partnership with Amgen for the development of oral biologics. This partnership resulted in a $25 million upfront payment and potential future milestones of up to $150 million.
Product Pipeline
AMTI focuses on products leveraging its proprietary platform for drug delivery. Key pipeline products include:
Financial Performance
| Year | Total Revenue | Net Income/(Loss) | Total Assets | Cash and Cash Equivalents |
|---|---|---|---|---|
| 2020 | $1.5 million | $(22.8) million | $30.1 million | $19.2 million |
| 2021 | $3.2 million | $(31.5) million | $32.7 million | $22.5 million |
| 2022 | $4.0 million | $(36.7) million | $36.1 million | $25.0 million |
| 2023 | $10.0 million (Projected) | $(38.2) million (Projected) | $40.0 million (Projected) | $30.0 million (Projected) |
Grants and Funding
AMTI has secured grants from government sources to support its research and development. In 2021, it received a NIH grant amounting to $3.5 million to further its research in drug delivery systems.
Market Potential
The total addressable market for AMTI's products is estimated to reach $25 billion by 2025, driven by the increasing demand for oral biologics and advanced drug delivery technologies.
Investment and Valuation
As of October 2023, AMTI has a market capitalization of approximately $500 million with a stock price hovering around $10 per share.
Future Growth Initiatives
AMTI aims to expand its commercial presence through:
Risks and Challenges
AMTI faces several challenges, including:
Applied Molecular Transport Inc. (AMTI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support